Mesoblast Historical Income Statement
| MESO Stock | USD 11.69 0.11 0.95% |
Historical analysis of Mesoblast income statement accounts such as Total Revenue of 5.6 M can show how well Mesoblast performed in making a profits. Evaluating Mesoblast income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Mesoblast's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Mesoblast latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mesoblast is a good buy for the upcoming year.
Mesoblast |
About Mesoblast Income Statement Analysis
Mesoblast Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Mesoblast shareholders. The income statement also shows Mesoblast investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Mesoblast Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Mesoblast generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Mesoblast. It is also known as Mesoblast overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Mesoblast's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Mesoblast current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.At this time, Mesoblast's Interest Income is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 3K | 831K | 1.8M | 1.9M | Reconciled Depreciation | 4.4M | 4.1M | 4.7M | 4.0M |
Mesoblast income statement Correlations
Click cells to compare fundamentals
Mesoblast Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mesoblast income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 3.7M | 4.3M | 4.4M | 4.1M | 4.7M | 4.9M | |
| Interest Expense | 13.3M | 10.7M | 16.9M | 19.4M | 20.7M | 21.7M | |
| Selling General Administrative | 25.6M | 30.9M | 27.2M | 25.4M | 23.6M | 20.5M | |
| Total Revenue | 32.2M | 7.5M | 10.2M | 7.5M | 5.9M | 5.6M | |
| Gross Profit | 6.8M | (25.3M) | (20.5M) | (20.2M) | (9.8M) | (9.3M) | |
| Other Operating Expenses | 107.6M | 115.1M | 90.8M | 76.8M | 64.7M | 71.6M | |
| Operating Income | (79.1M) | (111.9M) | (81.0M) | (69.1M) | (58.8M) | (61.7M) | |
| Ebit | (79.1M) | (83.7M) | (74.3M) | (65.5M) | (67.5M) | (70.9M) | |
| Research Development | 56.2M | 53.0M | 32.8M | 27.2M | 25.4M | 37.9M | |
| Ebitda | (75.4M) | (79.4M) | (69.9M) | (61.4M) | (62.8M) | (66.0M) | |
| Total Operating Expenses | 107.6M | 115.1M | 90.8M | 76.8M | 5.9M | 5.6M | |
| Income Before Tax | (87.4M) | (99.6M) | (91.6M) | (82.1M) | (88.1M) | (83.7M) | |
| Total Other Income Expense Net | (8.3M) | 9.5M | (11.0M) | (12.8M) | (29.4M) | (27.9M) | |
| Net Income | (77.9M) | (98.8M) | (91.3M) | (81.9M) | (88.0M) | (83.6M) | |
| Income Tax Expense | (9.4M) | (819K) | (239K) | (212K) | (191K) | (200.6K) | |
| Selling And Marketing Expenses | 25.3M | 32.7M | 30.8M | 27.7M | 15.7M | 25.0M | |
| Net Income From Continuing Ops | (77.9M) | (98.8M) | (91.3M) | (81.9M) | (88.0M) | (92.4M) | |
| Cost Of Revenue | 25.3M | 32.7M | 30.8M | 27.7M | 15.7M | 24.3M | |
| Net Income Applicable To Common Shares | (77.9M) | (98.8M) | (91.3M) | (81.9M) | (73.7M) | (77.4M) | |
| Tax Provision | (9.4M) | (819K) | (239K) | (212K) | (191K) | (200.6K) | |
| Net Interest Income | (14.7M) | (10.7M) | (17.3M) | (19.3M) | (18.8M) | (19.8M) | |
| Reconciled Depreciation | 3.7M | 4.3M | 4.4M | 4.1M | 4.7M | 4.0M | |
| Interest Income | 542K | 22K | 3K | 831K | 1.8M | 1.9M |
Pair Trading with Mesoblast
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.Moving together with Mesoblast Stock
| 0.83 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.77 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.62 | BHC | Bausch Health Companies | PairCorr |
Moving against Mesoblast Stock
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.76 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.76 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.72 | HLN | Haleon plc | PairCorr |
| 0.7 | RDY | Dr Reddys Laboratories | PairCorr |
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.41) | Return On Assets (0.05) | Return On Equity (0.18) |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.